How to Select the Correct Model: A Comparison of NB4 and Other Myeloid Leukemia Cell Lines (HL-60, U937, K562)

Introduction

In myeloid leukemia research, in vitro cell line models are fundamental tools for investigating disease mechanisms and developing new therapies. However, different cell lines possess unique genetic backgrounds and biological properties, which directly determine their suitability for specific studies. Selecting an inappropriate model can lead to experimental results that fail to accurately reflect the true pathological process, potentially leading to incorrect conclusions. Therefore, a thorough understanding of the similarities and differences among commonly used cell lines is critical. This article systematically compares four widely used myeloid leukemia cell lines: NB4, HL-60, U937, and K562. By analyzing their origins, core genetic features, and primary applications, the aim is to provide a clear decision-making framework for researchers to select the model that best fits their research objectives.

1. The NB4 Cell Line: A Specific Model for Acute Promyelocytic Leukemia (APL)

The NB4 cell line is the definitive model for studying acute promyelocytic leukemia (APL, FAB M3). It was established from an APL patient and its core genetic feature is the t(15;17)(q24;q21) chromosomal translocation, which results in the expression of the PML-RARα fusion protein. This fusion protein is the oncogenic driver of APL, responsible for blocking myeloid differentiation and promoting abnormal cell proliferation.

The key value of the NB4 cell line lies in its ability to accurately mimic the clinical pathology of APL. In vitro, it demonstrates high sensitivity to all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). ATRA induces NB4 cells to overcome the differentiation block and mature into neutrophilic granulocytes, while ATO promotes the degradation of the PML-RARα protein, ultimately leading to apoptosis. These responses are highly consistent with the clinical outcomes observed in APL patients undergoing targeted therapy. Consequently, when the research objective directly involves the function of PML-RARα, the pathogenesis of APL, or the evaluation of novel therapies targeting this fusion protein, NB4 is the indispensable choice.

The key tool for decoding PML-RARα function. Use our STR-verified NB4 cells to ensure a correct starting point for your APL mechanism research. Order now>>

2. The HL-60 Cell Line: A General Model for Myeloid Differentiation

The HL-60 cell line was derived from a patient with acute myeloid leukemia (AML, FAB M2). Unlike NB4, HL-60 does not harbor the PML-RARα fusion gene; its notable genetic feature is the amplification of the MYC proto-oncogene. This characteristic endows it with high proliferative potential and significant differentiation plasticity.

The broadest application of the HL-60 cell line is as a general model for studying myeloid cell differentiation. It can be induced to differentiate along different lineages by various chemical agents. For example, ATRA or dimethyl sulfoxide (DMSO) can induce its differentiation towards granulocytes, whereas phorbol esters (PMA) can direct it towards a monocyte-macrophage lineage. This multi-lineage potential makes HL-60 an ideal tool for investigating myeloid differentiation regulatory networks, signal transduction pathways, and for screening differentiation-inducing compounds. If the research focus is on the general mechanisms of myeloid differentiation rather than the specific pathology of APL, HL-60 is often a more suitable model than NB4.

Achieve reproducible experimental results. We provide stable, high-viability HL-60 cells, offering a reliable guarantee for your differentiation research. Click to check>>

3. The U937 Cell Line: A Dedicated Model for Monocytic Leukemia Research

The U937 cell line was established from a patient with histiocytic lymphoma but exhibits monocytic characteristics. It is therefore widely used as a model for studying monocytic leukemia and the function and differentiation of monocytes and macrophages. U937 cells lack the hallmark fusion genes of NB4 or K562, and their biological behavior primarily mimics that of the monocytic lineage.

In research, U937 is often used to explore biological processes related to monocytic function, such as chemotaxis, phagocytosis, and responses to inflammatory signals. Similar to HL-60, U937 can be treated with inducers like PMA to differentiate into mature, adherent macrophage-like cells. This provides a convenient system for studying the monocyte-to-macrophage transition and its role in immune responses and disease. When a research project focuses on the development or function of the monocytic lineage or related leukemias, U937 is the preferred tool.

4. The K562 Cell Line: The Classic Model for Chronic Myeloid Leukemia (CML)

The K562 cell line originated from a patient with chronic myeloid leukemia (CML) in blast crisis. Its defining genetic marker is the t(9;22)(q34;q11) translocation, known as the Philadelphia chromosome, which expresses the BCR-ABL1 fusion protein. This constitutively active tyrosine kinase is the core driver of CML.

The primary application of the K562 cell line is in studying CML pathogenesis and developing targeted drugs. It is the gold-standard model for testing the efficacy of BCR-ABL1 kinase inhibitors, such as imatinib. Furthermore, K562 cells exist at an early hematopoietic progenitor stage and possess multi-lineage potential, with the ability to be induced to differentiate towards erythroid, megakaryocytic, and monocytic lineages. This also makes them suitable for studying how BCR-ABL1 affects the differentiation decisions of hematopoietic progenitors. If the research is directly related to the BCR-ABL1 signaling pathway, the mechanisms of CML, or associated targeted therapies, K562 is the correct choice.

The cornerstone of CML research. Our K562 cells stably express BCR-ABL1, providing the ideal platform for your targeted therapy studies. View more>>

Model Selection Guide: A Decision Table

To facilitate a quick decision, the following table summarizes the core differences between the four cell lines.

Conclusion

Selecting the right cell line is a prerequisite for successful research in myeloid leukemia. The four cell lines—NB4, HL-60, U937, and K562—each represent the unique pathology and genetics of different types of leukemia. NB4 is dedicated to APL research, HL-60 serves as a general model for myeloid differentiation, U937 focuses on the monocytic lineage, and K562 is the standard tool for CML studies. Before initiating experiments, researchers should first define their core scientific question and then use the comparative information and decision table provided in this article to select the cell model that can most accurately answer that question.

References

[1]Lanotte, M., et al. (1991). A new model for acute promyelocytic leukemia studies: the NB4 cell line. Blood, 77(5), 1080–1086.

[2]Collins, S. J., et al. (1977). Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature, 270(5635), 347–349.

[3]Sundstrom, C., & Nilsson, K. (1976). Establishment and characterization of a human histiocytic lymphoma cell line (U-937). International Journal of Cancer, 17(5), 565–577.

[4]Lozzio, C. B., & Lozzio, B. B. (1975). Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood, 45(3), 321–334.